SURGICAL INNOVATIONS GROUP PLC

Regulatory Filings • Sep 13, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6175A

Surgical Innovations Group PLC

13 September 2018

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

Surgical Innovations Group plc

("SI Group" or the "Company")

CE mark certification obtained for CELLIS range

Surgical Innovations Group plc (AIM: SUN), the designer and manufacturer of innovative medical technology for minimally invasive surgery, provides a further update relating to the CELLIS range of products supplied to its UK distribution business, Elemental Healthcare Limited ("Elemental") by Meccellis Biotech SA ("Meccellis").

On 12 September 2018, Elemental received confirmation from Meccellis that CE certification has been issued in respect of the full range of CELLIS products previously sold by Elemental, and also covering innovative new products including the CELLIS Breast Pocket range launched at the London Breast meeting on 6 & 7 September 2018. The certificates are valid until August 2023.

Meccellis are now in a position to resume manufacture of these products, and detailed plans are in progress to facilitate a timely and controlled reintroduction to the UK market in coming weeks.

For further information please contact:

Surgical Innovations Group Plc	www.sigroupplc.com
Nigel Rogers, Executive Chairman	Tel: 0113 230 7597
Melanie Ross, COO and CFO
WH Ireland Limited (NOMAD & Broker)	Tel: 0113 394 6600
Tim Feather
Chris Viggor
Walbrook PR (Financial PR & Investor Relations)	Tel: 020 7933 8780 or si@walbrookpr.com
Paul McManus	Mob: 07980 541 893
Lianne Cawthorne	Mob: 07584 391 303

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

UPDEAPNAFLDPEFF